The Sentio System: Post-market Evaluation of Safety and Performance in Adolescents

The Sentio System: Post-market Evaluation of Safety and Performance in Adolescents With Mixed/Conductive Hearing Loss and Single Sided Deafness

This study is a post-market, multicentre, prospective, single arm investigation aimed to systematically collect safety and performance data on the Sentio system, when used as intended for adolescents (12-17 years inclusive).

Study Overview

• Status: Recruiting
• Conditions: Hearing Loss

• Study Type: Observational
• Enrollment (Estimated): 25

Contacts and Locations

• Study Contact: Name: Nicole Amichetti, PhD, MSc; Phone Number: 609-366-0424; Email: nitc@oticonmedical.com

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • Recruiting
      • Atlanta Institute for ENT
      • Contact: Jolie Fainberg, AuD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The investigation population will be comprised of the main patient groups indicated for the Sentio system: patients with either conductive/mixed hearing loss, SSD patients, or patients who for some reason cannot or will not use an AC CROS. The Sentio system is indicated for patients above the age of 12 and the investigation population will enroll adolescents between 12-17 years.

Description

Inclusion Criteria:

• Subjects must meet the following criteria to be eligible for participation in the investigation:

  1. Signed Informed Consent Form (signed by parent or legal guardian and child).
  2. Subjects aged 12 to 17 years of age (inclusive)

  3. Subjects with the following audiometric criteria consistent with the current and approved labeling of the device:

     3.1 Conductive or mixed hearing loss with a pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) of the indicated ear better than or equal to 45 dB HL.

     3.2 OR subjects with a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing (AC) thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz).

     3.3 OR subjects who are indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

  4. Prior experience with amplified sound through properly fitted amplification devices such as a hearing aid, a CROS device, or a non-surgical bone conduction solution (e.g., a softband or sound arc).
  5. For patients with conductive or mixed hearing losses sufficient (e.g., >25 dB) air bone gap (ABG) at the ear to be implanted.
  6. Subjects and parent(s) or legal guardian have the ability and willingness to comply with all investigational procedures/requirements, as determined by the Investigator.

Exclusion Criteria:

• Subjects meeting any of the following criteria will not be permitted to participate in the investigation:

  1. Medical condition(s) that contraindicates implant surgery or anesthesia.
  2. Untreated ongoing middle ear infection at the time of surgery.
  3. Known or suspected contact allergy to silicone or other material used in the Sentio system.
  4. Insufficient bone quality/quantity/depth or skull size for implantation of a Sentio Ti implant, assessed according to clinical practice.
  5. Known conditions that could jeopardize wound healing and skin condition e.g. uncontrolled diabetes over time or skin or scalp condition(s) that may preclude attachment to, or interfere with usage of, the sound processor as judged by the investigator.
  6. Subject that has received radiotherapy in the area of implantation or is planned for such radiotherapy or similar during the investigation period.
  7. For bilateral asymmetric* candidates, subjects already treated with a bone-anchored hearing solution on the side with the best BC thresholds.
  8. Known chronic or non-revisable vestibular or balance disorder.
  9. Known abnormally progressive sensorineural hearing loss.
  10. Currently participating, or participated within the last 30 days, in another clinical investigation involving an investigational drug or device that could impact the safety or effectiveness of the Sentio system as determined by the investigator.
  11. Use of active implantable or body worn devices that for medical reasons cannot be removed or discontinued, such as CSF shunts, implantable cardiac pacemakers, defibrillators, or neurostimulators.
  12. Known need for frequent MRI investigations for follow-up of other diseases.
  13. Current or known future use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator.
  14. Known retro cochlear pathology and auditory processing disorders that may have an impact on the outcome of the investigation.
  15. Any other known condition (e.g., developmental or learning delay or disability) that the investigator determines could interfere with compliance or investigation assessments.

  16. Any subject that according to the Declaration of Helsinki is deemed unsuitable for enrollment.

      • Defined as >10 dB difference measured across PTA of .5, 1, 2, & 3kHz

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
subjects

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
A. To demonstrate that the Sentio system improves hearing on the implanted ear.	3months post implantation

Collaborators and Investigators

• Sponsor: Oticon Medical

Study record dates

Study Major Dates

• Study Start (Actual): August 15, 2025
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): August 1, 2027

Study Registration Dates

• First Submitted: February 19, 2025
• First Submitted That Met QC Criteria: February 19, 2025
• First Posted (Actual): February 25, 2025

Study Record Updates

• Last Update Posted (Actual): September 22, 2025
• Last Update Submitted That Met QC Criteria: September 17, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Otorhinolaryngologic Diseases; Sensation Disorders; Ear Diseases; Hearing Disorders; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Hearing Loss
• Other Study ID Numbers: BC120

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No